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sion and metastasis.







Gastric cancer is one of the leading causes of cancer-related deaths
worldwide (Jemal et al., 2011; Jung et al., 2014). The prognosis of pa-
tients with gastric cancer remains poor, and in spite of improving surgi-
cal resection, combined with efﬁcient adjuvant therapy at the early
stages of thedisease, ensuing relapse andmetastasis often occurs.More-
over, advanced gastric cancers are resistant to traditional therapies and
modern treatments are ineffective (Camargo et al., 2014; Xu et al.,
2015). Although numerous oncogenes and tumor suppressor genes
have been reported to be responsible for the development and progres-
sion of gastric cancer (Hu et al., 2012), the molecular mechanisms un-
derlying the gastric cancer cell migration and invasion still remain
unclear.
Gastric cancer cells withmesenchymalmorphological changes show
increased motility and invasiveness due to decreased cell-cell contacts;
which are evocative of epithelial-mesenchymal transition (EMT) during
embryonic development (Katoh, 2005; Nieto, 2011; Brabletz, 2012; De
Craene and Berx, 2013). Since EMT generates cellswith invasive proper-
ties, able to move into surrounding normal tissues or organs, identiﬁca-
tion of signals that lead to EMT remains a central challenge in cancer
research. A hallmark of EMT is the functional loss of epithelial markersollege of Medicine, The Catholic
7-701, South Korea.
. This is an open access article underand the up-regulation of mesenchymal markers (Peinado et al., 2007).
Notably, abnormal activation of the Wnt/β-catenin signaling pathway
leads to β-catenin accumulation in the nucleus and subsequent binding
to the T cell factor (TCF) or lymphoid enhancer factor (LEF) transcrip-
tion factors, thereby inducing the expression of Wnt/β-catenin target
genes,which are essential for EMT andmetastatic progression of epithe-
lial cancers (Reya and Clevers, 2005; Nguyen et al., 2009; Zhang et al.,
2009; Khew-Goodall and Goodall, 2010). Therefore, a better under-
standing of the molecular mechanisms of Wnt/β-catenin signaling,
would provide a crucial insight into how EMT and cancer progression
might be regulated.
The NKX transcription factor family is involved in a variety of devel-
opmental processes (Alanentalo et al., 2006). Speciﬁcally, NKX6.3 tran-
script is localized in the epithelium of the mouse distal stomach region
and acts as a selective regulator of G- and D-cell lineages (Choi et al.,
2008). Recently, we have reported that somatic or epigenetic change
of the NKX6.3 gene was not found, whereas decreased DNA copy num-
ber of NKX6.3 and frequent allelic loss (52.2%) at the NKX6.3 locus was
detected in gastric cancer (Yoon et al., 2015). Moreover, we found that
NKX6.3 protein is expressed ubiquitously across all gastric glandular ep-
ithelial cells in humans, and functions as a key transcriptional regulator
of the genes that are involved in cell fate, including growth, differentia-
tion and death (Yoon et al., 2015; Yoon et al., 2016).We predicted that it
is likely that NKX6.3 plays an important role in maintaining gastric mu-
cosal integrity and may act as functional tumor suppressor. The physio-
logical relevance of the crosstalk between NKX6.3 and Wnt/β-catenin
signaling in cancer has yet to be elucidated.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tenin signaling in the progression of gastric cancer. Our study reveals
that NKX6.3 is a critical regulator of theWnt/β-catenin, Rho-GTPase sig-
naling pathways and gastric cancer progression.2. Materials and Methods
2.1. Human Gastric Samples
A total of 65 frozen gastric cancerswere obtained from the Chonnam
National University Hwasun Hospital, which is supported by the Minis-
try of Health, Welfare and Family Affairs. Informed consent was provid-
ed according to the Declaration of Helsinki. Written informed consent
was obtained from all subjects. The study was approved by the Institu-
tional Review Board of The Catholic University of Korea, College ofMed-
icine (MC15SISI0015). There was no evidence of familial cancer in any
of the patients.2.2. Immunohistochemistry for NKX6.3
For the immunohistochemical analysis, tissue microarray recipient
blocks were constructed containing 157 gastric cancer tissues from for-
malin-ﬁxed parafﬁn embedded specimens. Three tissue cores from each
cancer (2 mm in diameter) were taken and placed in a new recipient
parafﬁn block using a commercially available microarray instrument
(Beecher Instruments, Micro-Array Technologies, Silver Spring, MD,
USA), according to establishedmethods (Kononen et al., 1998). One cyl-
inder of normal gastric mucosa adjacent to each tumor was also trans-
ferred to the recipient block. 2 μm sections were cut the day before
use and stained according to standard protocols.
To maximize immunohistochemistry signal, two strategies were
used: antigen retrieval in citrate buffer, and signal ampliﬁcationwith bi-
otinylated tyramide, as previously described (Park et al., 2000). The sec-
tions were incubated overnight at 4 °C with NKX6.3 antibodies (1/100;
Atlas antibodies, Stockholm, Sweden). Detection was carried out using
biotinylated goat anti-rabbit antibodies (Sigma, St. Louis, MO, USA),
followed by incubationwith a peroxidase-linked avidin-biotin complex.
Diaminobenzidine was used as a chromogen, and the slides were coun-
terstained with Mayer's hematoxylin. Staining for NKX6.3 antigen was
considered positive when N30% of the nucleus was stained positively.
The results were reviewed independently by two pathologists. For neg-
ative controls, primary antibodies were replaced with non-immune
serum.2.3. Cell culture and Transfection of NKX6.3, Skp2, c-Myc and Mutant β-
cateninS37A
AGS and MKN1 gastric cancer cells lines were cultured as described
in Supplementary information. Complete NKX6.3, Skp2, c-Myc andmu-
tant β-cateninS37A-cDNAwas cloned into the expression vector pCMV6-
Myc-DDK (Origene), pcDNA3.1 (Invitrogen) and pQNCX2 (gift from Dr.
Eek Hoon Jho, University of Seoul, Seoul, South Korea). We generated
stable NKX6.3 transfectants of AGS and MKN1 cells, AGSNKX6.3 and
MKN1 NKX6.3, stably expressing human NKX6.3, as well as mock
transfectants, AGSMock and MKN1Mock cells, as described previously
and in the Supplemental information (Yoon et al., 2015). Stable expres-
sion of NKX6.3 was conﬁrmed in AGSNKX6.3 and MKN1NKX6.3 cells by
western blot analysis.2.4. Cell migration, Invasion Assay and Spheroid Culture
Cell migration, motility, invasion assays and spheroid culture as de-
scribed in Supplementary information.2.5. Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed using the Thermo Scientiﬁc Pierce Aga-
rose ChIP kit (Thermo Scientiﬁc Pierce), as described previously and in
the Supplemental information (Yoon et al., 2015). DNA ampliﬁcation
was performed by ChIP-qPCR using primers for the promoter described
in the Supplemental information.
2.6. Cloning of the ChIP Fragments
The immunoprecipitated DNA was cloned as described previously
(Yoon et al., 2015). Brieﬂy, the DNA isolated from ChIP was heated at
68 °C for 5min and then cooled to 37 °C. One to two units of T4DNA po-
lymerase were added to the DNA and reaction mix containing repair
buffer (18 mM ammonium sulfate, 66 mM Tris [pH 8.0], 6.6 mM
MgCl2, 50 mM β-mercaptoethanol, and 0.5 mM of each nucleotide)
and subsequently incubated at 37 °C for 15min. The reactionwas termi-
nated by 1 μl of 0.5 M EDTA for a 50 μl reaction mix. The processed DNA
was cloned into pUC118 Hinc II/BAP vector (Takara). Each ligation was
transformed into DH-5α competent cells (Clontech). The entire trans-
formation was plated onto ampicillin treated Luria broth agar plates.
Randomly picked 120 colonies with inserts were identiﬁed by PCR
using M13 primers spanning the cloning site in the vector. Inserts
N200 bp were selected for sequencing using a capillary automatic se-
quencer (3730 DNA Analyzer, Applied Biosystem). The BLAST search
of the human genome database at NCBI was performed to locate se-
quences. The possible genomic binding sequences were identiﬁed by
pattern matching. Speciﬁc sequences were also analyzed using BLAST
adjusted to short sequences (Program= blastn, Word size = 7, Expect
Value = 100, Filter = disabled). The sequence logo was generated by
WebLogo (http://weblogo.berkeley.edu/logo.cgi).
2.7. RNA Isolation and Quantitative Reverse Transcriptase (RT)-PCR
Total RNAwas extracted fromgastric cancer tissues and cell lines fol-
lowing the TRIzol Reagent (Invitrogen) protocol. Two micrograms of
total RNA was used in reverse transcription following the Superscript
III (Invitrogen) protocol. Quantitative RT PCR was performed on an
IQ5 optical system (Bio-rad) using SYBR Green Q-PCR Master Mix
(Bio-rad), as described previously and in the Supplemental information
(Yoon et al., 2015). Gene expression data were normalized to GAPDH.
2.8. Immunoblot and Immunoﬂuorescence (IF)
The effect of NKX6.3 on expression of Wnt/β-catenin, Rho-GTPase
signaling and EMT-related proteins including E-cadherin, β-catenin, γ-
catenin, Snail, Slug, Vimentin, Zo-1, and ZEB1 was determined in AGS-
Mock, MKN1Mock, AGSNKX6.3 and MKN1NKX6.3 by Western blot, immuno-
ﬂuorescence and confocal microscopy, as described previously and in
the Supplemental information (Yoon et al., 2011).
2.9. Co-Immunoprecipitation (Co-IP)
AGSMock, MKN1Mock, AGSNKX6.3 and MKN1NKX6.3 cells were washed
with PBS and lysed at 4 °C with PBS, pH 7.2 containing 1.0% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, 10 mM NaF, 1.0 mM NaVO4, and
1.0% protease inhibitor cocktail (Sigma, St. Louis, MO, USA) as described
previously (Yoon et al., 2015). Brieﬂy, equal protein aliquots (1.0 mg)
were immunoprecipitated with 2.0 μg of antibodies to β-catenin
(Sigma), E-cadherin (Sigma), and GSK3β (Cell Signaling, Danvers, MA,
USA) plus protein A/G-agarose (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Immunoprecipitated proteins were resolved on 12% SDS-
polyacrylamide gels and transferred to PVDFmembranes (BioRad, Rich-
mond, CA, USA). The membranes were reacted with antibodies against
α-, β-, and γ-catenin, E-cadherin, GSK3β, Axin1, and APC each diluted
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were stripped and re-probed for GAPDH (Santa Cruz Biotechnology).
2.10. Statistical Analysis
Student's t-test was used to analyze the effects of NKX6.3 on cell mi-
gration and invasion, ChIP and mRNA expression. Expression of NKX6.3
and clinicopathological factors were analyzed using the Chi-square test.
Pearson and linear regression tests were used to analyze the expression
of NKX6.3, Wnt/β-catenin and Rho-GTPase signaling-related genes in
gastric cancer tissues. Data are expressed as mean ± SEM from at
least three independent experiments. A P-value less than 0.05 was con-
sidered to be the limit of statistical signiﬁcance. All experiments were
performed in triplicate to verify the reproducibility of ﬁndings.
3. Results
3.1. Altered NKX6.3 Expression Is Strongly Associated with Gastric Cancer
Progression
Our previous study showed that NKX6.3 expression was signiﬁcant-
ly reduced in gastric cancers (Yoon et al., 2015). To investigate whether
NKX6.3 contributes to gastric cancer progression, we performed real-
time QPCR and western blot in gastric cancer tissues. Expression levels
of NKX6.3mRNA transcript were signiﬁcantly lower in gastric cancers
with higher T stage (P b 0.05), lymph node metastasis (P b 0.05), and
TNM stage (P b 0.05), when compared to gastric cancers with tumor
stage T1, without lymph node metastasis (N0) or with TNM stage I
(Fig. 1a–c and Table S1). To conﬁrm our results, we recapitulated
NKX6.3 gene expression levels in a large cohort of gastric cancer patients
(NCBI GEO database, accession numbers GSE27342) and found that
NKX6.3 expressionwas alsomarkedly decreased in sporadic gastric can-
cers with TNM stage II, III, and IV (Fig. 1d).
We also examined the protein expression of NKX6.3 in 65 gastric
cancer tissues and corresponding non-tumorous gastric mucosal tis-
sues. Expression of NKX6.3 was absent and/or markedly reduced in
tumor tissues of gastric cancer patients with TNM stages II and III (Fig.
1e).Whenwe analyzed the correlation betweenNKX6.3 protein expres-
sion and clinical covariates of these 65 gastric cancer patients, the pro-
tein expression of NKX6.3 was not associated with age, gender, site, or
histological type (P N 0.05). It was, however, signiﬁcantly associated
with lymph node metastasis (P b 0.0001), depth of invasion (P =
0.0001) and TNM stage (P b 0.0001) in gastric cancer tissues (Table
S1). Next, we conﬁrmed the expression and localization of NKX6.3 pro-
tein by immunohistochemistry in 157 humangastric cancer tissue spec-
imens. In normal gastric mucosa, we detected NKX6.3 immuno-
reactivity in the nucleus of gastric epithelial cells (Fig. 1ﬁ). In gastric
cancer tissues, NKX6.3 protein was expressed in neoplastic cells in 33
of 157 (21%) specimens, localized mainly in the nucleus (Fig. 1ﬁi and
iii). In addition, its expression was detected in 13 (19.1%) and 20
(22.5%) of 68 intestinal- and 89 diffuse-type gastric cancer, respectively.
In contrast, there was no NKX6.3 immunostaining in any of the gastric
cancer tissues (Fig. 1ﬁv). Statistically, there was signiﬁcant relationship
between altered expression of NKX6.3 protein and the clinicopathologic
parameters, including depth of invasion and lymph node metastasis
(Chi-Square test, P b 0.05) (Table S1). Importantly, Kaplan-Meier analy-
sis revealed that patients that do not express NKX6.3 had on average a
24-month shorter overall survival time, when compared to patients
with positive NKX6.3 expression. The median survival time was 49.8
and 73.9months for patientswith negative and positive NKX6.3 expres-
sion, respectively (hazard ratio (HR) 0.4577, 95% CI 0.2870-0.7301, P =
0.0069; Fig. 1g). In GEO database (accession number GSE26253), pa-
tients with low NKX6.3 mRNA expression showed signiﬁcantly worse
recurrence free survival (mean of 38.4 versus 82.2 months, hazard
ratio (HR) 0.3176, 95% CI 0.2560-0.3941, P b 0.0001; Fig. 1h) than
those with high NKX6.3mRNA expression.3.2. NKX6.3 Regulates EMT-Related Proteins Implicated in Gastric Cancer
Cell Migration and Invasion
To determine whether NKX6.3 contributes to gastric cancer cell mi-
gration and invasion, we performed in vitro wound healing, transwell
chemotaxis, spheroid-migration and Matrigel invasion assays. Cell mi-
gration activity of NKX6.3-stable transfectants at 2, 4, 8 and 16 h after
seeding into the wound area, was similar to that of mock-stable cells
(Fig. 2a). However, NKX6.3 in AGSNKX6.3 and MKN1NKX6.3 cells signiﬁ-
cantly suppressed cell migration at 3 and 4 days after culture in
transwell microchemotaxis assays (Fig. 2b). Migration of the spheroidal
cancer cells was dramatically reduced in NKX6.3 stable transfectants, at
2, 3, and 4 days after seeding (Fig. 2c).
In a Matrigel assay, invasiveness of gastric cancer cells was signiﬁ-
cantly inhibited in NKX6.3 stable transfectants, compared to that of
mock stable cells at 1, 2, 3, and 4 days after culture (Fig. 2d and S1).
Since EMT is a critical process in cell migration and invasion (Scheel
and Weinberg, 2012; Puisieux et al., 2014), we further analyzed the
function of NKX6.3. As expected, in cancer cells, NKX6.3 expression
regulated the expression of EMT-related proteins, such as E-cadherin,
Zo-1, N-cadherin, β-catenin, Snail, Slug, Vimentin and ZEB-1 (Fig. 2e
and f). In addition, NKX6.3 directly bound to the promoter regions
of SNAI2 and VIM, and regulated the EMT-related gene transcripts
(Fig. 2g–i and S2). These results suggest that NKX6.3 may inhibit gastric
cancer cell migration and invasion by regulating EMT-related protein
expression.3.3. NKX6.3 Controls the Wnt/β-Catenin Signaling Pathway
TheWnt/β-catenin signaling pathway induces the transcription fac-
tor for the EMT-related gene expression and subsequently plays a cru-
cial role in cancer progression and metastasis (Jamora et al., 2003;
Reya and Clevers, 2005; Nguyen et al., 2009; Zhang et al., 2009;
Khew-Goodall and Goodall, 2010; Qi et al., 2015). Additionally, abnor-
mal Wnt/β-catenin signaling is associated with progression, invasion
and metastasis in gastric cancer (Utsunomiya et al., 2000; Zhou et al.,
2002; Zhang and Xue, 2008). Thus, we examined if NKX6.3 regulated
components of the Wnt/β-catenin signaling pathway. In NKX6.3 stable
transfectants, expression of Wnt3a, Wnt5a, p-LRP6, Dvl2, Dvl3, p-Akt,
β-catenin and Catenin-δ was markedly decreased, whereas that of p-
β-catenin, APC, Axin1, GSK-3βY216, and β-Trcp was increased (Fig. 3a).
In immunoprecipitation assays with β-catenin and GSK3β, β-catenin
was present in the TCF4/TCF3/LEF1 immunocomplex in AGSMock and
MKN1Mock cells. NKX6.3, however, rendered β-catenin to bind to the
β-catenin destruction complex, comprising GSK3β, Axin1, APC, and β-
Trcp, in AGSNKX6.3 and MKN1NKX6.3 cells (Fig. 3b and c). Furthermore,
restoration of E-cadherin induced by NKX6.3, led to E-cadherin/p120-
catenin/σ-catenin/β-catenin complex formation (Fig. 3d). Immunoﬂuo-
rescent assay also detected loss of nuclearβ-catenin expression and res-
toration of E-cadherin in AGSNKX6.3 and MKN1NKX6.3 cells (Fig. 3e). We
previously reported that NKX6.3 was found to be a transcription factor
for various genes (Yoon et al., 2015). As such, we further examined
the role of NKX6.3 as a transcription factor for Wnt/β-catenin signaling
pathway-related genes by ChIP-cloning and sequencing analysis. As
shown in Fig. 3f, 43 genes related to the Wnt/β-catenin signaling and
EMTwere predicted target genes of NKX6.3. Notably, ChIP analysis con-
ﬁrmed that NKX6.3 binding activity increased in promoter regions of se-
lected Wnt/β-catenin signaling pathway-related genes, such asWnt3a,
Wnt5a, CTNNB1, APC and CDH1 (Fig. 3g). In addition, the mRNA expres-
sion levels ofWnt3a,Wnt5a and CTNNB1were decreased, and those of
APC and CDH1were increased in AGSNKX6.3 andMKN1NKX6.3, when com-
pared to AGSMock andMKN1Mock cells (Fig. 3h, i and S3). Taken together,
these results suggest that NKX6.3maymodulate the expression of EMT-
related proteins via transcriptional regulation of theWnt/β-catenin sig-
naling pathway-related genes.
Fig. 1. NKX6.3 expression in gastric cancer tissues. (a–c) Expression levels of NKX6.3mRNA transcript were signiﬁcantly lower in gastric cancer samples with; higher T stage (a), lymph
node metastasis (b) and TNM stage (c). The results shown are as mean ± SEM of three independent experiments in the same tumors. Numbers in brackets correspond to number of
patients. (d) NKX6.3 gene expression was decreased in a large cohort of gastric cancer patients with TNM stage II, III and IV (GSE27342). Numbers in brackets correspond to number of
patients. (e) Expression of NKX6.3 protein was lost in gastric tumor tissues of patients of TNM stage II and III. (f) Immunohistochemical analysis of NKX6.3 expression in 157 human
gastric tissue specimens. NKX6.3 immunostaning is present throughout the nucleus of gastric mucosa epithelial cells from normal gastric mucosa (i) or intestinal- (ii) and diffuse-type
(iii) gastric cancer. In contrast, no NKX6.3 immunoreactivity is present in intestinal-type gastric cancer (iv). (g) Kaplan-Meier plots indicate the overall survival for gastric cancer
patients categorized by NKX6.3 expression (n = 33 for positive NKX6.3 group versus n = 124 for negative NKX6.3 group). P value is determined by log-rank test. Association between
NKX6.3 expression and clinicopathologic parameters. (h) Kaplan-Meier plot of distant recurrence free survival in a large cohort of 430 gastric cancer patients with low (n = 251) or
high (n = 179) NKX6.3mRNA expression.
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gration and Invasion
Wnt proteins induce cancer cell growth, migration and invasion,
through the activation of β-catenin and RhoA signaling pathways
(Heasman and Ridley, 2008). Additionally, activation of the Wnt/β-ca-
tenin signaling pathway is frequently caused by Wnt pathway gene al-
terations in certain cancers including gastric cancer (Miyoshi et al.,
1992; Clements et al., 2002). In cells with β-cateninmutations, β-caten-
in translocates to the nucleus and leads to aberration of the downstream
target genes, such as c-Myc (He et al., 1998). To investigate whetherNKX6.3 is critical for suchWnt- andmutant β-catenin-mediated effects,
we examined the impacts of NKX6.3, Wnt proteins (3a and 5a, respec-
tively) and mutant β-cateninS37A on cell growth, migration and inva-
sion. In AGSMock and MKN1Mock cells, an increase in Wnt proteins and
mutant β-cateninS37A dramatically stimulated cell growth, whereas an
increase in NKX6.3 failed to promote Wnt- and mutant β-cateninS37A-
mediated cell growth (Fig. 4a and b). In addition,Wnt proteins induced
mRNA and protein expression changes of Wnt/β-catenin and RhoA sig-
naling related genes, such as CTNNB1, Skp2, MYC, RhoA, APC and CDH1
(Fig. 4c, e, g and S4). However, NKX6.3 inhibited the Wnt-induced
mRNA and protein expression of these genes (Fig. 4c, e, g and S4).
Fig. 2. NKX6.3 inhibits gastric cancer cell migration and invasion. (a–c) In vitro wound healing assay, the effect of NKX6.3 cell migration activity was similar to that of mock-stable cells
within 16 h (a). NKX6.3 signiﬁcantly suppressed cell migration at 3 and 4 days after culture in a transwell chemotaxis assay (b). Migration of the spheroidal cancer cells was
dramatically reduced in AGSNKX6.3 and MKN1NKX6.3 at 2, 3 and 4 days after culture (c). The results shown are as mean ± SEM of three independent experiments. (d) Invasiveness of
gastric cancer cells was signiﬁcantly inhibited in AGSNKX6.3 and MKN1NKX6.3 in a Matrigel-invasion assay. Results represented the mean ± SEM in three independent experiments. (e
and f) NKX6.3 induced increased expression of E-cadherin, p-β-catenin and γ-catenin proteins, and reduced expression of N-cadherin, β-catenin, Snail, Slug and Vimentin proteins in
western blot assay (e). In an immunoﬂuorescent assay, NKX6.3 enhanced Zo-1 and reduced Vimentin and ZEB-1 protein expression (f). (g) ChIP-qPCR analysis of NKX6.3 binding to
the promoter of SNAI2 and VIM. The results represent mean ± SEM from three independent experiments. (h) NKX6.3 suppresses SNAI2 and VIM mRNA expression. The results
represent mean ± SEM from three independent experiments. Data were statistically analyzed by Student's t-test. (i) Heat-maps show the expression ratios of EMT-related genes
modulated by NKX6.3 in AGS and MKN1 cells using quantitative real-time PCR. On the scale bar, yellow indicates up-regulation and blue indicates down-regulation of mRNA
compared to mock. Data represent medians of three independent experiments.
101J.H. Yoon et al. / EBioMedicine 9 (2016) 97–109
Fig. 3. NKX6.3 controls theWnt/β-catenin signaling pathway. (a) Immunoblots forWnt/β-catenin signaling pathway-related genes. NKX6.3 inhibits the expression of positive regulators,
such asWnt3a andβ-catenin, and induces that of negative regulators, such as APC andβ-Trcp. (b and c)NKX6.3 renderedβ-catenin to bind to theβ-catenin destruction complex of GSK3β,
Axin1, APC, andβ-Trcp in an immunoprecipitation assay. (d) In immunoprecipitation assay, E-cadherin expression induced byNKX6.3 led to E-cadherin/p120catenin/σ-catenin/β-catenin
complex formation. (e) Immunoﬂuorescent staining ofβ-catenin and E-cadherin. NKX6.3 inhibits nuclearβ-catenin expression and induces E-cadherin expression in AGS andMKN1 cells.
(f) Venn diagram and a list show that 43 predicted target genes of NKX6.3 are related to theWnt/β-catenin signaling and EMT. (g) ChIP-qPCR analysis of NKX6.3 binding to the promoters
ofWnt3a,Wnt5a, CTNNB1, APC and CDH1. The results represent mean ± SEM from three independent experiments. (h) NKX6.3 suppressesWnt3a,Wnt5a, and CTNNB1 and induces APC
and CDH1 mRNA expression. The results represent mean ± SEM from three independent experiments. Data were statistically analyzed by Student's t-test. (i) Heat-maps show the
expression ratios of Wnt/β-catenin signaling pathway-related genes modulated by NKX6.3 in AGS and MKN1 cells using quantitative real-time PCR. On the scale bar, yellow indicates
up-regulation and blue indicates down-regulation of mRNA compared to mock. Data represent medians of three independent experiments.
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Fig. 4. NKX6.3 abrogates Wnt- and mutant β-cateninS37A-induced cancer cell migration and invasion. (a) Wnt proteins dramatically increased cell growth, but NKX6.3 failed to promote
Wnt-mediated cell growth. The results represent cell growth asmean± SEM from three independent experiments. Datawere statistically analyzed by Student's t-test. (b) NKX6.3 inhibits
mutantβ-cateninS37A-mediated cell growth. The results represent cell growth asmean±SEM from three independent experiments. Datawere statistically analyzedby Student's t-test. (c)
Heat-maps ofWnt-mediated gene expression ratios in AGS andMKN1 cells, examined using quantitative real-time PCR. On the scale bar, yellow indicates up-regulation and blue indicates
down-regulation of mRNA compared to mock. The results shown are as mean ± SEM of three independent experiments. (d) Heat-maps of mutant β-cateninS37A-mediated gene
expression ratios in AGS and MKN1 cells examined using quantitative real-time PCR. On the scale bar, yellow indicates up-regulation and blue indicates down-regulation of mRNA
compared to mock. Data are expressed as medians of three independent experiments. (e and g) Wnt proteins induced changes in mRNA (e) and protein (g) expression of Wnt/β-
catenin and Rho-GTPase signaling related genes, such as p-LRP6, Dvl2, Dvl3, CTNNB1 and RhoA. NKX6.3 inhibited the Wnt-induced mRNA and protein expression of these genes. The
results shown are as mean ± SEM of three independent experiments. (f and h) Real-time PCR (f) and western blot analysis (h) showed that mutant β-cateninS37A induced mRNA and
protein expression of c-Myc, Skp2 and RhoA. NKX6.3 signiﬁcantly reduced the mRNA and protein expression of these genes. Results represented the mean ± SEM of three independent
experiments. (i–l) Chemotaxis migration (i and k) and invasion (j and l) assays demonstrated that treatment with Wnt proteins and transfects with mutant β-cateninS37A induced cell
migration and invasion. NKX6.3 suppressedWnt- and mutant β-cateninS37A induced cell migration and invasion. The results are mean ± SEM of three independent experiments.
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Fig. 5. NKX6.3 controls Rho-GTPase family proteins expression. (a) Western blot analysis showed that the expression of all Rho-GTPase family proteins was signiﬁcantly decreased in
AGSNKX6.3 and MKN1NKX6.3 cells. The expression of CD2AP was increased in NKX6.3 stable AGSNKX6.3 and MKN1NKX6.3 cells. (b) Immunoﬂuorescence analysis detected strong
expression of RhoA, Cdc42, and Rac1 proteins in the cytoplasm of AGSMock and MKN1Mock cells. NKX6.3 signiﬁcantly reduced the expression of these proteins in AGSNKX6.3 and
MKN1NKX6.3 cells. (c–f) ChIP-qPCR analysis of NKX6.3 binding to the promoter of RhoA (c), Cdc42 (d), Rac1 (e) and Rac2 (f) and their mRNA expression change examined by real-time
QPCR. The results are expressed as mean ± SEM of three independent experiments. (g) Heat-maps showing expression ratios of Rho-GTPase signaling pathway-related genes
modulated by NKX6.3 in AGS and MKN1 cells using quantitative real-time PCR. On the scale bar, yellow indicates up-regulation and blue indicates down-regulation of mRNA
compared to mock. Data are expressed as medians of three independent experiments.
104 J.H. Yoon et al. / EBioMedicine 9 (2016) 97–109Moreover, mutant β-cateninS37A inducedmRNA and protein expression
of MYC, Skp2 and RhoA, whereas NKX6.3 signiﬁcantly reduced
the expression of these genes (Fig. 4d, f, h and S5). We next examined
whether NKX6.3 prevented Wnt and mutant β-cateninS37A induced
cell migration and invasion. The chemotaxis migration and invasion
assays demonstrated that treatment with Wnt protein and transfection
with mutant β-cateninS37A promoted cell migration and invasion,Fig. 6. NKX6.3 functions as a negative transcriptional regulator for RhoA. (a) NKX6.3 binding
independent experiments. (b) NKX6.3 signiﬁcantly reduced Skp2 and c-Myc mRNA express
experiments. Data were statistically analyzed by Student's t-test. (c) In AGSMock and MKN1M
inhibited the complex formation in Co-IP assay. (d) Co-transfection of NKX6.3 stable cells w
and Skp2 expression. (e and f) Ectopic expression of both c-Myc and Skp2 signiﬁcantly enha
results are mean ± SEM of three independent experiments.whereas NKX6.3 suppressed the stimulatory effects of Wnt and
mutant β-cateninS37A on cell migration and invasion (Fig. 4i–l). These
results suggest that NKX6.3 inhibits Wnt and mutant β-cateninS37A
induced cell migration and invasion by inactivation of Wnt- and mutant
β-cateninS37A-mediated β-catenin and RhoA signaling pathways and
regulation of β-catenin downstream genes, even in the presence of mu-
tant β-catenin.to the promoter of Skp2 and c-Myc. The results are expressed as mean ± SEM of three
ion in real-time QPCR. The results are expressed as mean ± SEM of three independent
ock cells, c-Myc bound to p300/CBP-Skp2-Miz1 and Max proteins, but NKX6.3 markedly
ith both c-Myc and Skp2. RhoA protein was expressed only in the cells with both c-Myc
nced binding activity at the RhoA promoter and increased RhoA mRNA expression. The
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106 J.H. Yoon et al. / EBioMedicine 9 (2016) 97–1093.5. NKX6.3 Controls the Expression of Rho-GTPase Family Proteins
The Rho/ROCK pathway plays an important role in invasion andme-
tastasis in gastric cancer (Matsuoka and Yashiro, 2014). Moreover, the
increased expression of RhoA and Rac1 among the Rho-GTPase family
proteins is associated with gastric cancer progression (Pan et al.,
2004). To determinewhether NKX6.3 reduces gastric cancer cell migra-
tion through down-regulation of the Rho-GTPase family, we examined
the expression of CD2-associated protein (CD2AP), RhoA, Cdc42, p-
Rac1/Cdc42 and Rac1/2/3 proteins, in AGSNKX6.3 and MKN1NKX6.3 cells.
Western blot analysis showed that expression of all Rho- GTPase family
proteins was signiﬁcantly decreased, whereas the expression of CD2AP,
functioning as a scaffolding protein between cytoskeletal and cell mem-
brane proteins during cell migration (Mustonen et al., 2005), was in-
creased in NKX6.3 stable transfectants, AGSNKX6.3 and MKN1NKX6.3
cells (Fig. 5a). In immunoﬂuorescence analysis, strong expression of
RhoA, Cdc42, and Rac1 proteins was detected in the cytoplasm of AGS-
Mock andMKN1Mock cells, whereas expression of NKX6.3 signiﬁcantly re-
duced the expression of these proteins in AGSNKX6.3 and MKN1NKX6.3
cells (Fig. 5b). In ChIP and real-time QPCR assays, the binding capacity
of NKX6.3 to the promoter regions of RhoA, Cdc42, Rac1 and Rac2
genes was dramatically increased in NKX6.3 stable transfectants and
mRNA transcript expression of those genes was signiﬁcantly decreased
in NKX6.3 expressing cells (Fig. 5c–g and S6).
3.6. NKX6.3 Functions as a Negative Transcriptional Regulator for RhoA
TheMyc-Skp2-Miz1 transcriptional complex is critical for RhoA tran-
scription, cell migration and invasion (Chan et al., 2010). To analyze the
effect of NKX6.3 on the c-Myc-Skp2-Miz1 transcription complex, we
performed ChIP assays to ﬁrst address whether NKX6.3 binds to the
Skp2 and c-Myc promoter regions. As we expected, NKX6.3 bound to
the Skp2 and c-Myc promoter (Fig. 6a) and signiﬁcantly reduced Skp2
and c-Myc mRNA expression in real-time QPCR (Fig. 6b). Next, we ex-
amined the effect of NKX6.3 on the formation of the Myc-Skp2-Miz1-
p300 complex by co-IP. In AGSMock and MKN1Mock cells, c-Myc bound
to p300/CBP-Skp2-Miz1, and Max proteins, however NKX6.3 markedly
inhibited the complex formation (Fig. 6c). In addition, co-transfection
with both c-Myc and Skp2 in NKX6.3 stable transfectants signiﬁcantly
increased NKX6.3 binding activity to the promoter region of RhoA (Fig.
6d) and induced RhoAprotein andmRNAexpression (Fig. 6e and f). Fur-
thermore, ectopic expression of both c-Myc and Skp2 in AGSNKX6.3 and
MKN1NKX6.3 cells signiﬁcantly increased cell migration and invasion
(Fig. 6g and h). Taken together, these results suggest that NKX6.3 may
suppress gastric cancer cell migration and invasion by inhibiting the
Myc-p300/CBP-Skp2-Miz1 transcriptional complex formation required
for RhoA expression.
3.7. NKX6.3 Is Correlated With Wnt/β-catenin and Rho-GTPase Related
Genes in Gastric Cancer Tissues
To further conﬁrm that NKX6.3 reduces gastric cancer cell migration
and invasion, we analyzed 33Wnt/β-catenin, Rho-GTPase signaling-re-
lated genes in 65 gastric cancer tissues using real-time QPCR analysis
and the gene expression proﬁles were compared with T stage, lymph
node metastasis, and TNM stage. As shown in Fig. 7a, distinctive gene
expression proﬁles were observed according to the T stage, lymph
node metastasis, and TNM stage (Fig. 7a; Fig. S7a and b). In addition,
the expression of positive and negative regulators of Wnt/β-catenin
and Rho-GTPase signaling pathways were up- and down-regulated in
gastric cancer tissues, respectively (Fig. 7b). Furthermore, Pearson cor-
relation matrices revealed positive (blue) and negative (red) relation-
ships between altered genes (Fig. 7c). Then we examined whether the
expression level of NKX6.3 mRNA transcript associates with those of
Wnt/β-catenin, Rho-GTPase signaling pathways, cell adhesion and
EMT-related genes. Pearson correlation values for the positively (blue)associated genes ranged from 0.98 (NKX6.3 versus AES) to 0.07
(NKX6.3 versus MIZ1); and for the inversely (red) associated genes
ranged from −0.25 (NKX6.3 versus MAX) to −0.99 (NKX6.3 versus
CLDN1) (Fig. 7d). As expected, when we compared relative mRNA ex-
pression of the above genes between gastric cancer cases with low (I/
II) and high (III/IV) TNM stage, the expression of genes that were posi-
tively correlatedwith NKX6.3was signiﬁcantly decreased, whereas that
of negatively correlated ones was dramatically elevated (Fig. 7e). Next,
we determined the expression of NKX6.3, E-cadherin, N-cadherin,β-ca-
tenin, p-GSK3βY216, CLND1, RhoA, Cdc42, Rac1/2/3, Snail, Slug and
Vimentin proteins in 7 gastric cancer tissues at different TNM stages
and compared with expression in non-tumorous gastric mucosal tis-
sues. Notably, expression of CLND1, β-catenin and Vimentin proteins
was increased in gastric cancer tissue from patients with TNM stage II
or III (Fig. 7f). In contrast, p-GSK3βY216 expressionwas increased in gas-
tric cancer tissues frompatientswith TNMstage I, but reduced in gastric
cancer tissues from patients with TNM stage II or III. Finally, we con-
clude that NKX6.3 may inhibit the progression of gastric cancer by
down-regulating β-catenin signaling pathway and Rho-GTPase family.
4. Discussion
Disruption of gastric epithelial homeostasis may result in abnormal
cell proliferation, invasion, andmetastasis, which are recognized as can-
cer hallmarks. During tumor progression, subsequent invasiveness is
thought to herald the onset of the last stage of a multi-step process
that eventually leads to metastatic dissemination with life-threatening
consequences (Thiery, 2002).
EMT has been shown to occur in wound healing, organ ﬁbrosis and
the initiation of cancer metastasis (Kalluri and Weinberg, 2009). EMT
in cancer cells of epithelial origin is a crucial step that precedes the in-
duction ofmotility and invasive potential duringmetastatic progression
(Chaffer and Weinberg, 2011; Dave et al., 2012). Numerous studies re-
vealed signaling pathways, such as TGF-β, NF-κB, and Wnt/β-catenin
that are involved in regulation of EMT (Lee et al., 2006; Chaudhury et
al., 2010; Howard et al., 2011; Lamouille et al., 2014). It was reported
that theWnt signaling pathway inhibits GSK3β and stabilizesβ-catenin,
which translocates to the nucleus to engage LEF and TCF transcription
factors, resulting in induction of a gene expression program that pro-
motes EMT (Lamouille et al., 2014). Aberrant Wnt signaling caused by
abnormal expression of Wnts, and β-catenin mutations, is associated
with the development and progression of several malignancies, includ-
ing gastric cancer (Kurayoshi et al., 2006; El Wakil and Lalli, 2011).
Recently, we found that the NKX6.3 protein functions as a key tran-
scriptional regulator, controlling cell growth, differentiation and death,
and inhibits gastric tumorigenesis (Yoon et al., 2015; Yoon et al.,
2016). In this study, we have investigatedwhether NKX6.3 is implicated
in gastric cancer progression mechanisms and acts as functional tumor
suppressor through affecting Wnt/β-catenin and Rho-GTPase signaling
pathways. Here, we show that NKX6.3 expression level is negatively as-
sociatedwith tumor stage, lymph nodemetastasis, and TNM stage in 65
gastric cancer tissues (Fig. 1). In vitro, NKX6.3 signiﬁcantly inhibits mi-
gration and invasion of gastric cancer cells (Fig. 2). Interestingly, NKX6.3
induced E-cadherin and γ-catenin expression with a concomitant de-
cline in mesenchymal marker expression, including N-cadherin, Snail,
Slug, and Vimentin, suggesting that NKX6.3 is able to inhibit EMT of gas-
tric cancer cells, not only by inducing epithelial differentiation, but also
by suppressingmesenchymal phenotype (Fig. 2). Moreover, NKX6.3 di-
rectly bound to promoter regions of SNAI2 and VIM and reduced mRNA
transcripts of the SNAI2 and VIM genes, which are important for behav-
ioral changes related to the adhesion and migration properties for local
tumor invasion (Fig. 2). In addition, NKX6.3 induced β-catenin binding
to the β-catenin destruction complex (Stamos andWeis, 2013), includ-
ing GSK3β, Axin1, APC, and β-Trcp, in NKX6.3 stable gastric cancer cells.
The resultant re-expression of E-cadherin promoted byNKX6.3 led to E-
cadherin/p120-catenin/α-catenin/β-catenin complex formation and
Fig. 7.NKX6.3 is negatively correlatedwithWnt/β-catenin and Rho-GTPase signaling pathway genes in gastric cancer tissues. (a) Heat-maps demonstrate the expression ratios of NKX6.3,
33 Wnt/β-catenin and Rho-GTPase signaling-related genes, examined using quantitative real-time PCR in 65 gastric cancer tissues. On the scale bar, yellow indicates up-regulation and
blue indicates down-regulation of mRNA compared to non-tumorous gastric mucosal tissues. Data are expressed as medians of three independent experiments. (b) Expression of
NKX6.3 and 33 Wnt/β-catenin and Rho-GTPase signaling pathway genes in gastric cancer tissues compared to corresponding non-tumorous gastric mucosal tissues. Data are
expressed as medians of three independent experiments. (c) Pearson correlation matrices revealed positive (blue) and negative (red) relationships between altered genes. (d) Pearson
correlation with NKX6.3, Wnt/β-catenin, Rho-GTPase, cell adhesion and EMT-related genes (blue, positive correlation; red, negative correlation). (e) The effects of NKX6.3 on
expression of 33 Wnt/β-catenin and Rho-GTPase signaling pathway genes in gastric cancer tissues with TNM stage (blue dot, stage I, II; red dot, stage III, IV). Data are expressed as
medians from three independent experiments. (f) Expression of NKX6.3, E-cadherin, N-cadherin, β-catenin, p-GSK3βY216, CLND1, RhoA, Cdc42, Rac1/2/3, Snail, Slug and Vimentin
protein expression in 7 gastric cancer tissues at different TNM stages and corresponding non-tumorous gastric mucosal tissues. Notably, N-cadherin, β-catenin, CLND1, RhoA, Cdc42,
Rac1/2/3, Snail, Slug and Vimentin protein expression was increased in tumor tissues of gastric cancer patients with TNM stage II or III.
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identiﬁed a repertoire of NKX6.3 candidate target genes including EMT-
related genes and those involved in the regulation of theWnt/β-catenin
signaling pathway (Fig. 3f). NKX6.3 signiﬁcantly inhibited Wnt- and
mutant β-catenin-induced cell growth, migration and invasion by sup-
pressing the Wnt/β-catenin downstream target genes, including c-Myc
and RhoA (Fig. 4).
The Ras homologous (Rho)-GTPase family proteins, including RhoA,
Cdc42, and Rac1, are known to play a key role in cancer development
and progression mechanisms, including cell transformation, prolifera-
tion, migration, invasion and metastasis by regulating the actin cyto-
skeleton and cell-cell adhesion (Mitchison and Cramer, 1996;
Lauffenburger and Horwitz, 1996; Olson et al., 1998; Ridley, 2000;
Fukata and Kaibuchi, 2001). Notably, Skp2 induces RhoA transcription,
cell migration and invasion by recruiting p300 and Miz1 to the c-Myc
complex (Chan et al., 2010).
To elucidate the molecular mechanism by which NKX6.3 inhibits
gastric cancer cell migration, we investigated the role of NKX6.3 in
Rho-GTPase family protein expressions. Expectedly, NKX6.3 signiﬁcant-
ly decreased the protein expression of RhoA, Cdc42, p-Rac1/Cdc42, and
Rac1/2/3 in gastric cancer cells (Fig. 5). Furthermore, we found that
NKX6.3 functions as a negative transcriptional regulator of RhoA,
Cdc42, Rac1, Rac2, Skp2 and c-Myc genes and completely inhibits c-
Myc-p300/CBP-Skp2-Miz1 and Max complex formation, thereby
preventing gastric cancer cell migration and invasion (Fig. 6).
Finally, the analysis of 33Wnt/β-catenin and Rho-GTPase signaling-
related genes in 65 gastric cancer tissues showed distinctive gene ex-
pression proﬁles according to the tumor stage, lymph node metastasis,
and TNM stage. NKX6.3 expression was positively correlated with ex-
pression of Wnt/β-catenin and Rho-GTPase signaling inhibitors, such
as APC and GSK3β, and inversely correlated with expression of Wnt/
β-catenin and Rho-GTPase signaling pathway activators, such as
Wnt3a, Wnt5a, CTNNB1, RhoA and Snail (Fig. 7), conﬁrming that
NKX6.3 acts as an inhibitor forWnt/β-catenin andRho-GTPase signaling
pathways.
Our results support the studies in which Wnt/β-catenin and Rho-
GTPase signaling pathways stimulated gastric cancer malignant trans-
formation and progression. In summary, our ﬁndings offer evidence
for the functional importance of NKX6.3 in inhibition of EMT and cancer
cell migration through suppressingWnt/β-catenin and Rho-GTPase sig-
naling pathways and the NKX6.3 inactivation could be one of the key
mechanisms of gastric cancer cell invasion and metastasis.Conﬂict of Interest Statement
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